>>Signaling Pathways>> Immunology/Inflammation>> Aryl Hydrocarbon Receptor>>Tapinarof (WBI 1001)

Tapinarof (WBI 1001)

Catalog No.GC31732

Tapinarof(WBI 1001)(WBI-1001)는 13nM의 EC50을 갖는 천연 아릴 탄화수소 수용체(AhR) 작용제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Tapinarof (WBI 1001) Chemical Structure

Cas No.: 79338-84-4

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$89.00
재고 있음
5mg
US$81.00
재고 있음
10mg
US$135.00
재고 있음
25mg
US$258.00
재고 있음
50mg
US$405.00
재고 있음
100mg
US$675.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Tapinarof is a natural aryl hydrocarbon receptor (AhR) agonist with an EC50 of 13 nM.

Tapinarof activates the AhR pathway through direct binding. Tapinarof dose-dependently induces nuclear translocation of AhR in immortalized keratinocytes (HaCaT) (EC50=0.16 nM)[1].

Tapinarof acts through AhR to reduce inflammation in IMQ-treated mice. AhR-sufficient mice on a C57Bl/6 background exhibit a reduced clinical score after treatment with Tapinarof or 6-formylindolo(3,2-b)carbazole (FICZ). In contrast, AhR KO mice do not respond to the anti-inflammatory effects of Tapinarof. FICZ is used as a comparator in these studies and yields similar results, with dramatically reduced inflammatory responses in wild-type, but not AhR KO mice[1].

[1]. Smith SH, et al. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans. J Invest Dermatol. 2017 Oct;137(10):2110-2119.

리뷰

Review for Tapinarof (WBI 1001)

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tapinarof (WBI 1001)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.